Nucleophosmin and P27 immunohistochemical markers expression in acute myeloid leukemia

Background: Significant improvements have been done in identification of pathogenesis and prognostic factors in acute leukemia. There is not enough documents for nucleophosmin 1(NPM1) as independent prognostic and therapeutic factor in these patients. Acute myeloid leukemia with this genetic mutation is a distinct entity in WHO 2008 classification of acute myeloid leukemia. P27 mutation correlates with disease free survival (DFS) in acute myeloid leukemia. In this study, we evaluate NPM1 and P27 mutation frequencies and consider their relation with clinical and laboratory markers.Materials and methods: In this retrospective study, we chose 30 bone marrow biopsies with distinct diagnosis of acute myeloid leukemia in Qhaem department of pathology from 1389 to 1392. Bone marrow sections were stained with NPM1 and P27 markers. We evaluated clinical and laboratory data of patients and followed them as death event for 1 year.Results: 60% of patients were male and 40% of them were female. Mean age was 36.53 + 18.5. NPM1 and P27 were detected in 9(29%) and 7(23%) patients respectively. Mean survival of patients with NPM1 and P27 were 9and 10 months respectively. There was significant difference between leukocytosis with NPM1 (P=0.010) and P27 mutations (P=0.033).Conclusions: White blood cells count was higher in patients with nucleophosmin 1 and P27 mutations than patients without these mutations . Specific treatment modalities in acute myeloid leukemia may have been developed , based on clinical and laboratory charactristics of these mutations .

کلیدواژه ها:

Acute myeloid leukemia ، Nucleophosmin 1 ، P27